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Osteopontin regulation in cultured rat renal epithelial cells. Osteopon-
tin is a secreted, arginine-glycine-aspartate (RGD)-containing phospho-
protein that is up-regulated in kidney cortical tubular epithelial cells in
many experimental models of tubulointerstitial fibrosis. Its close associa-
tion with infiltrating macrophage in this disease and its ability to directly
stimulate macrophage migration has made it a key target as a molecule
likely to be important in mediating renal inflammation. The mechanism
responsible for osteopontin up-regulation in kidney disease is unknown,
but may involve induction by specific cytokines released by damaged
glomeruli or other parts of the kidney, prior to the onset of interstitial
disease. We have investigated this hypothesis by testing the effects of
angiotensin 11, bFGF, TGF/31, EGF, and IGF, important renal cytokines,
on osteopontin regulation in cultured NRK52E cells, a rat renal epithelial
cell line. Using Northern blot, Western blot, and ELISA analyses, we find
that NRK52E cells constitutively express low levels of osteopontin mRNA
and protein. TGF1 and EGF are potent inducers of osteopontin mRNA
and protein in these cells. mRNA stability and nuclear run on assays
suggest that induction of osteopontin expression by TGF1 and EGF is via
increased transcription of the osteopontin gene. In contrast, IGF-l,
angiotensin II, and PDGF BB did not significantly modulate osteopontin
expression in NRK52E cells. These studies are consistent with the
hypothesis that release of potent cytokines by the injured kidney might be
one mechanism whereby elevated levels of osteopontin are synthesized by
cortical tubular epithelial cells early in tubulointerstitial disease.
Tubulointerstitial disease accompanies most types of glomeru-
lar and extraglomerular renal diseases, and is characterized by
infiltration of mononuclear cells, atrophy and dilation of tubules,
and increased deposition of collagen in the interstitium [1]. A
growing number of studies suggest that leukocyte accumulation in
the interstitium plays a major causal role in development of this
disease [2—5]. The importance of the tubulointerstitial injury has
been underscored by studies that have demonstrated that the
severity of the tubulointerstitial disease correlates with both the
degree of renal impairment and risk of progression to end-stage
kidney failure [6, 7]. Thus, determining the mechanisms that
control the development of tubulointerstitial fibrosis is of major
importance.
We have recently focused on osteopontin as a potential regu-
lator of tubulointerstitia! injury. Osteopontin is an RGD-contain-
ing acidic glycoprotein with cell adhesive and chemotactic prop-
erties in vitro [reviewed in 8]. In the kidney, osteopontin is
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normally made by the descending thin limb of the loop of Henle
and some collecting ducts of the medulla, but is virtually absent
from renal cortical or juxtaglomerular tubules [9]. Osteopontin is
found in urine where it may act as an inhibitor of calcium oxalate
crystal growth [10]. In contrast, osteopontin levels are strikingly
elevated in experimental models of renal disease associated with
cortical tubulointerstitial fibrosis [9, 11]. Osteopontin has also
been shown to be elevated in animal models of tubulointerstitial
disease caused by cyclosporine, protein overload, and unilateral
ureteral obstruction [12—141. In all cases, a striking association of
osteopontin with sites of macrophage accumulation was noted. In
vivo and in vitro, osteopontin is a chemotactic and adhesive factor
for macrophages [15—17], suggesting that osteopontin might play
a role in modulating the inflammatory response observed under
these conditions.
However, given the multiplicity of its receptors and diverse
functions, osteopontin might play multiple roles during renal
injury and repair. For example, osteopontin levels were enhanced
in tubular epithelial cells following IGF-1 pretreatment in isch-
emic rat kidneys [18]. Since IGF-1 accelerated the recovery of
normal renal function and morphology post-ischemia [19], this
suggested that osteopontin might serve to promote tissue regen-
eration and tissue remodeling after acute ischemic injury of the
kidney. In this context, it is interesting that osteopontin levels
were decreased in human transplant kidneys that showed rejec-
tion compared to nonrejecting kidneys, suggesting that osteopon-
tin levels might be important to the success of kidney engraftment
[20]. In support of this concept, osteopontin has been shown to
inhibit cytokine-induced iNOS synthesis and nitric oxide produc-
tion in human tubular epithelial cells suggesting a possible cell
protective function [21]. Regardless of its functions, the fact that
diverse injuries to the kidney results in osteopontin elevation
suggests that: (1) osteopontin might be an important common
mediator of renal injury and repair and (2) osteopontin synthesis
is tightly regulated in the kidney.
Despite the overwhelming number of studies showing the
association of osteopontin with renal disease, we know very little
about the regulation of osteopontin in kidney epithelial cells. We
have hypothesized that cytokines released by the injured kidney
might he responsible for the observed changes in osteopontin
expression following injury [22]. The purpose of the present study
was to identify regulators of osteopontin expression in renal
epithelial cells focusing on cytokines that have been implicated in
renal interstitial disease. Therefore, we examined the effect of
various cytokines on osteopontin mRNA and protein synthesis in
NRK52E cells, a well characterized rat renal epithelial cell line.
1766
Malyankar et al: Osteopontin regulation in kidney cells 1767
Our studies suggest that TGF1 and EGF are potent inducers of
osteopontin synthesis in NRK52E cells. These cytokines appear to
act predominantly via transcriptional mechanisms to regulate
osteopontin synthesis in renal epithelial cells.
Methods
Cells
A normal rat kidney epithelial cell line, NRK52E [23], was
obtained from ATCC at passage 15 and cultured in DMEM-high
glucose media containing 10% calf serum. These cells have
previously been shown to secrete C-type natriuretic peptide [24],
contain EGF [23, 25] and TGFJ3 receptors [26].
Cylokine treatment
Cells were grown to confluence and treated on day 0 with the
following cytokines or vehicle alone in serum-free media: Angio-
tensin II (1 jiM; Sigma, St. Louis, MO, USA), bFGF (10 ng/ml;
Collaborative Research, Bedford, MA, USA), TGFJ31 (10 ng/ml;
a gift from Dr. Purchio, Bristol-Meyers Squibb Pharmaceutical
Research Institute, Seattle, WA, USA), PDGF-BB (10 ng/ml; a
gift from Dr. Charlie Hart, Zymogenetics, Seattle, WA, USA),
EGF (50 nglml; R & D Systems, Minneapolis, MN, USA), and
IGF-1 (50 ng/ml; R & D Systems).
Northern blot analysis
Total RNA was isolated using the TRIZOL method (Gibco,
Grand Island, NY, USA) and electrophoresed in a denaturing 1%
agarose gel as previously described [27]. After transfer to Zeta-
Probe, the filters were probed with 32P-labeled 2B7, a rat os-
teopontin cDNA, as previously described [271. Data were normal-
ized to 28S ribosomal RNA [28]. Quantitation was performed
using the phosphorimager facility of the Markey Molecular Med-
icine Center at the University of Washington.
Western blot and ELISA analyses
Conditioned medias were collected from each treatment group
and protein content measured using the microBCA assay. Twenty
microliters of each were electropheresed on a 10% SDS-poly-
acrylamide gel, transferred and blotted for osteopontin using
MPIIIBIO [1] (obtained from the Developmental Studies Hybrid-
oma Bank maintained under NICHD contract N01-HD-6-2915)
as previously described [291. A second 20 jig aliquot was analyzed
by ELISA using MPIIIBIO(1) as the capture antibody and 0P199,
an anti-rat osteopontin polyclonal antibody [30], as the detection
antibody. Wells of a Nunc maxisorp plate were coated with 1 jig
MPIIIBIO(1) in 50 j.tl PBS for two hours at room temperature.
Wells were washed with PBS and then incubated with blocking
solution (2% BSAJ1% normal rabbit serum in PBS). After
washing, conditioned media containing 20 jig of total protein, or
known concentration of purified rat osteopontin, were added to
the wells and incubated for two hours at room temperature, or
overnight at 4°C. After washing with PBS, 250 ng 0P199 was
added in blocking solution and incubated at room temperature for
one hour. After washing with PBS, 50 jil of ABC solution
(Vectastain Elite ABC kit; Vector, Burlingame, CA, USA) was
added and incubated for 45 minutes at room temperature. After
washing with PBS, color was developed using the chromogenic
substrate o-phenylcnediamine. Reactions were stopped with 100
jil of 4.5 M sulfuric acid. Absorhance was measured at 490 nm, and
concentrations of osteopontin determined by comparison to a
standard curve generated using purified rat osteopontin [30] on
the same plate.
Actinomycin D treatment
Cells were treated with EGF and TGFf31 as described above for
72 hours. Actinomycin D (12.5 jig/mI) was added to the medium
and total RNA was isolated at different time points following
treatment. Northern blot analysis, normalization, and quantita-
tion were carried out as described above.
Nuclear run-on assays
Nuclear run-on assays were performed using a modification of
previously described protocols [31, 32]. Cells were treated with
EGF and TGF1 as described above and nuclei were isolated as
described previously [32]. The run-on reaction was carried out as
described previously except that the a(32P)-UTP labeled RNA
was purified using the Trizol method. Labeled RNA was hybrid-
ized to 5 jig of linearized plasmid DNA that had been previously
bound to Zetaprobe membrane (Bio-Rad, Hercules, CA, USA).
Plasmid DNAs used were 2B7 (osteopontin), pBA-1 (gamma
actin cDNA which cross reacts with alpha, beta and gamma actin
[33]), and control plasmid containing no insert, pUC7 (NEB,
Beverly, MA, USA). Equal amounts of labeled RNAs (5 X 106
cpm) were added to the membranes. Hybridization was carried
out at 65°C for 36 hours in hybridization buffer (0.25 M Na2HPO4,
pH 7.2 and 7% SDS). The membranes were washed at 65°C under
conditions of high stringency (20 mivi Na2HPO4, pH 7.2 and 5%
SDS twice for 20 mm each; 20 mi Na2HPO4, pH 7.2 and 1% SDS
twice for 20 mm each) and quantitated using a phosphorimager.
Results
Osteopontin mRNA levels
In order to examine regulators of osteopontin expression in rat
kidney epithelial cells, NRKS2E cells were treated with a variety
of renal cytokines that have been implicated in renal disease. As
shown in Figure 1, NRKS2E cells constitutively express low levels
of osteopontin mRNA. Treatment of cells with TGF/31 and EGF
increased osteopontin mRNA levels within a 24 hour period.
Levels of mRNA increased at 48 hours and were highest at 72
hours following treatment. TGFf31 was the strongest inducer,
showing an —8.5-fold induction of osteopontin mRNA at 72 hours
followed by EGF that showed an —-7.0-fold induction at 72 hours.
In contrast, IGF-1, bFGF, PDGF BB, and angiotensin II did not
appreciably alter osteopontin expression levels in NRK52E cells,
even though optimal receptor binding concentrations of cytokines
were used. Similar results were obtained in a second independent
experiment (not shown).
Osteopontin protein levels
In order to determine whether increased steady state levels of
osteopontin mRNA translated into increased osteopontin synthe-
sized and secreted by NRK52E following cytokine treatment, we
performed Western blot analysis of conditioned media samples.
As shown in Figure 2A, very little osteopontin protein was
normally secreted by NRK52E cells, although small amounts
could be seen on prolonged exposure of the blot (not shown). This
was consistent with the low mRNA levels observed by Northern
blot analysis (Fig. 1). Addition of either EGF or TGFi elevated
SSWSWe*esss6 Sp$SSSeSesØ
1768
9
8-
7-
6-
5-
3-
2-
1—
Malyankar et al: Osteopontin regulation in kidney cells
osteopontin protein level in the media of NRK52E cells with
highest levels seen at two and three days after treatment. The
predominant form of osteopontin observed under these condi-
tions had an apparent molecular weight of 66 kDa, consistent with
the size previously reported in rat kidney and smooth muscle cells
[9, 291. However, in the TGFf31 treated cells, an additional
immunoreactive band was observed at 68 kDa. We suspect that
this band may represent a differentially phosphorylated, glycosy-
lated, or spliced isoform of osteopontin. No increase in osteopon-
tin protein was seen in cells treated with IGF-1, PDGF BB,
angiotensin II or hFGF (data not shown). Equivalent loading was
demonstrated by Coomassie staining of a duplicate gel (Fig. 2B).
To obtain more precise quantitation of the levels of OPN
secreted by these cells under various conditions, we developed a
sandwich ELISA for rat osteopontin. Two different antibodies
were tested for their ability to act as capture or detection
antibodies for this assay: 0P199 and MPIIIB1O(1). As shown in
Figure 3A, the sandwich ELISA was most quantitative if
MPIIIB1O(1) was used as the capture antibody (coated on the
wells) and 0P199 used as the detection antibody. Using these
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Fig. 1. Northern blot analysis of osteopontin
mRNA in NRK52E rat renal epithelial cells. A.
NRK52E cells were treated with the indicated
cytokines or vehicle-alone (no serum) for 24,
48, or 72 hours, and total RNA harvested andI I Northern blotted using an osteopontin cDNA(OPN). Methylene blue staining of the filtershows equivalent loading (28S). WKY12-22,mRNA derived from rat aortic smooth musclecells which contains high levels of osteopontin0)0 U- 0 L run as a positive control. B. Quantitation of
. F- osteopontin mRNA levels shown in (A) by0 phosphorimaging. Values arc normalized to 28Sa.
ribosomal RNA and expressed as arbitrary
units. A second experiment perfomed
independently showed similar results.
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Fig. 2. Western blot of osteopontin protein
secreted by 1'/RK52E rat renal epithelial cells.
NRK52E cells were treated with TGFI3I, EGF
or no serum, for I, 2, or 3 days and conditioned
media were collected, electrophoresed, and
either Western blotted using anti-rat
osteopontin antibody, MPIITB1O(1) (A) or
stained with Coomassie Blue (B). A second
experiment performed independently showed
similar results (not shown).
conditions, a sensitive ELISA with a linear range spanning ito 20
nglwell was developed (Fig. 3B).
To confirm the utility of this assay, we performed sandwich
ELISA analysis on the samples examined by Western blot analysis
in Figure 2A. As shown in Figure 4, we found that NRK52E cells
secrete very little osteopontin protein (< 0.1 jig/mI) normally,
whereas treatment with TGF/31 increased levels to 1.4 jig/mI at 48
hours and 2 jig/mI at 72 hours. Conditioned media from EGF
treated cells contained 0.45 jig/mI after 48 hours and 0.9 jiglml
after 72 hours of treatment. These data are qualitatively in good
agreement with the relative amounts of osteopontin observed by
Western blot analysis of the same samples (Fig. 2).
Osleopontin mRNA stabilily
To explore the mechanism of regulation of the osteoporitin
gene by cytokines in kidney cpithelial cells, we performed mRNA
stability and transcription analyses using the NRK52E cells. To do
this we chose to focus on EGF and TGF1 treatments, since these
produced the greatest increases in osteopontin expression in this
cell type.
The increased steady-state levels of osteopontin mRNA in-
duced by TGFI31 and EGF in NRK52E cells might be due to
stabilization of the osteopontin mRNA by TGFp1, increased
transcription of the osteopontin gene, or both. To examine the
half-life of osteopontin mRNA, we first treated cells with TGFJ31
or EGF for 72 hours to induce maximum osteopontin mRNA
levels, and then treated the cells with actinomycin D to block
further mRNA synthesis. We then measured osteopontin mRNA
decay with time by Northern blot analysis. As shown in Figure 5
osteopontin mRNA is quite stable in cells treated with EGF as
well as the control cells, the half life of the osteopontin mRNA in
both cases being> 12 hours. On the other hand, TGFI3I induced
a dramatic dc-stabilization of the osteopontin mRNA. The half
life of osteopontin mRNA in the TGFf3I and Actinomycin D
treated cells was —one hour. These data suggest that changes in
osteopontin mRNA stability do not account for the increases in
steady-state mRNA levels seen after treating these cells with EGF
and TGFI3I. On the contrary, because of the enhanced turnover
of osteopontin mRNA in the TGFf31 treated cells, very high or
sustained transcription of the osteopontin gene appears to be
required for the induction of osteopontin mRNA under these
conditions.
Osteopon tin gene transcription
Since a change in mRNA stability did not appear to account for
the changes in steady state levels of osteopontin mRNA following
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Fig. 3. ELISA development for rat osteopontin quantitation. A. Microtiter
wells were coated with either MPIIIB1O(1) or 0P199, and ELISA analysis
performed using 0P199 or MPIIIB1O(1) as the detection antibody.
Symbols are: (U) MPIIIBW(1) as capture antibody with 0P199 as
detection antibody; (0) 0P199 as capture antibody with MPIIIBIO(1) as
detection antibody. Points represent average of duplicates. B. ELISA
standard curves using MPHIB1O(1) as capture antibody and 0P199 as
detection antibody. Purified rat smooth muscle derived osteopontin was
used as the standard antigen. Each point represents the average of
triplicates SD.
cytokine treatment, we performed nuclear run on assays to
measure transcription rate of the osteopontin gene. As shown in
Figure 6, transcription of the osteopontin gene was increased by
both TGFJ3I and EGF in NRK52E cells. Relative quantitation of
duplicate experiments indicated an average of an eightfold in-
crease in transcriptional activity in TGF/3 1-treated cells and a
23-fold increase in EGF treated cells after 72 hours. Run on
assays were also performed on NRK52E cells after 24 and 48
hours of treating the cells with EGF and TGF1. The EGF-
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Fig. 4. Quantitation of osteopontin protein secreted by NRKS2E cells.
ELISA analysis was performed on NRK52E cell conditioned media 24, 48,
and 72 hours following treatment with the indicated cytokines or vehicle
alone (no serum). Osteopontin levels are expressed as jig/mi conditioned
media. Each point represents the average of triplicates SD.
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Fig. 5. Effect of TGF[31 and EGF on osteopontin mRNA stability. NRK52E
cells were treated with the cytokines or control (no cytokines) for 72 hours
and then treated with actinomycin D (12.5 jig/mI) for different time points.
Total RNA was harvested and used for Northern blot analysis. RNA levels
were normalized using 28S RNA and arbitrary values were plotted relative
to the zero time point (relative mRNA levels). Symbols are: (A) control;
(•) EGF; (•) TGFB.
treated cells showed a fivefold increase after 24 hours and a
19-fold increase after 48 hours, and the TGFJ3I-treated cells
showed an eightfold increase in 24 hours and ninefold increase in
48 hours. These data were normalized against the actin gene after
subtracting background obtained using pUC7 plasmid as a nega-
tive control. These data, as well as the mRNA stability studies,
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Fig. 6. Effect of TGF1 and EGF on
osteopontin gene transcnption. NRK52E cells
were treated with the cytokines or control (no
serum) for 72 hours and used in nuclear run-on
assays as described in the Methods section.
Radiolabeled nascent transcripts were
hybridized to filter-immobilized plasmids
containing either osteopontin (opn), actin, or
control (pUC7) cDNAs. Results shown are
representative of two independent experiments.
suggest that EGF and TGF1 act at a transcriptional level to
elevate steady-state osteopontin mRNA levels in rat kidney
epithelial cells.
Discussion
Osteopontin has been implicated as an important mediator of
tubular injury and repair in a number of different acute and
chronic renal injury models [11—14, 18, 34]. The mechanism(s)
responsible for osteopontin up-regulation during renal disease is
unknown, but may involve induction by specific cytokines released
by damaged glomeruli, inflammatory cells or injured regions [22].
Our studies suggest that TGFf31 and EGF may be important
regulators of osteopontin synthesis in renal epithelial cells.
TGFI31 and EGF induced both the level of osteopontin mRNA
and protein synthesized by a rat renal epithelial cell line, NRK52E
cells. These cells, like cortical tubular epithelial cells in vivo,
normally synthesize very low levels of osteopontin. Using actino-
mycin D and nuclear run on assays, we found that both TGFI3I
and EGF appear to elevate osteopontin levels secreted by
NRK52E cells primarily by enhancing the transcription rate of the
osteopontin gene rather than stabilizing the mRNA. Thus, cis-
acting sequences in the osteopontin gene together with specific
trans-acting factors most likely regulate osteopontin gene expres-
sion in response to TGFJ3I and EGF in rat renal epithelial cells.
In vivo, TGFI3 and EUF have both been implicated in renal
injury and repair processes. TGF has been correlated with
glomerular and interstitial fibrosis in experimental models of
protein overload proteinuria [13], passive-Heymann nephritis
[351, anti-GBM nephritis [36], obstructive uropathy [37], and in
human and animal models of diabetic nephropathy [38, 391. In
addition, infusion of anti-TGFI3 [40] or expression of decorin [411,
a natural inhibitor of TGFp, suppressed matrix production by
glomeruli and buildup of mesangial matrix in rat glomerulonc-
phritis. Most recently, inhibition of TGF/3 has been shown to
significantly attenuate the characteristic features of diabetic renal
involvement, including glomerular hypertrophy and increased
matrix expression [421. Thus, TGF appears to be a major
regulator of renal glomerular and interstitial fibrosis in vivo.
On the other hand, EGF levels decrease in the kidney during
mercuric chloride induced acute renal failure [43], and urinary
EGF levels decrease in ischemia-induced acute tubular necrosis
(ARF) [441 and nephrotoxic ARF [51 Infusion of EGF enhances
recovery from acute renal failure induced by either ischemia [461
or mercuric chloride nephrotoxicity [71, suggesting important
roles in renal regeneration mechanisms. Thus, TGF and EGF
may play distinct, but important roles in regulating the various
phases of the renal response to injury. Since osteopontin is a
downstream product of all of these cytokines, it is interesting to
speculate that it may play an important role in common final
pathway(s) required for renal injury and repair processes such as
inflammation, fibrosis, and cellular regeneration.
To our knowledge, these are the first studies to demonstrate
TGF1 and EGF induction of osteopontin mRNA in cultured
kidney epithelial cells. TGFf31 has also been shown to elevate
osteopontin mRNA and protein levels in an osteosarcoma cell
line, ROS 17/2.8 and normal rat bone cells [48], and rat aortic
smooth muscle cells [29]. IGF-I has not been previously reported
to regulate osteopontin in any cell system, but has been implicated
in renal osteopontin expression in vivo [18]. Other cytokines which
have been reported to induce osteopontin levels include bFGF in
ROS 17/2.8 osteosarcoma cells [491 and rat aortic smooth muscle
cells [18], angiotensin II (Ang II) in rat aortic smooth muscle cells
[18], PDGF in rat aortic smooth muscle cells [501, LIF in
MC3T3-E1 mouse osteoblast cells [51], and IL-la and TNFcs in
primary mouse osteoblasts and MC3T3-E1 cells [52].
TGFf31 and EGF stimulated steady-state levels of osteopontin
mRNA, which was reflected in elevated amounts of osteopontin
protein secreted by NRK52E cells. Our studies indicate that the
mechanisms by which TGF1 and EGF up-regulate steady state
osteopontin expression in kidney cells occur predominantly at the
transcriptional level. These data suggest that cis-acting sequences
in the osteopontin promoter interacting with specific trans-acting
factors probably control the elevated steady-state osteopontin
mRNA expression observed in response to TGFj31 and EUF.
Transcriptional regulation of the osteopontin gene has also been
reported for TGFj31 [53] in rat osteosarcoma cells. Interestingly,
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our data also suggest that other mechanisms besides gene tran-
scription rate and mRNA stabilization may play a role in control-
ling steady state levels of osteopontin mRNA. We found that
TGFl and EGF induced comparable levels of steady state
mRNA, despite the finding that the rate of transcription was lower
in TGFI31 treated cells than EGF-treated cells, and TGFj3I
tended to destabilize the osteopontin mRNA compared to EGF
treatment. TGF/31 might enhance splicing of the osteopontin
precursor mRNA, stability of the mRNA in the nucleus, or
transport to the cytoplasm, thus accounting for the higher steady
state levels. The assays perfomed in this study would not permit us
to distinguish between these possibilities. TGF/31 induced desta-
bilization of mRNA is not unique to osteopontin, since TGFJ31
also caused a rapid degradation of c-kit mRNA in FDC-P1 [54].
TGFj3I also inhibits the expression of iNOs in rat pulmonary
aortic smooth muscle cells at both the protein and RNA level [55].
Hence, TGFf3 may have effects on several levels of gene expres-
sion.
Finally, a number of cytokines failed to induce osteopontin in
NRK52E cells. Most surprisingly, Ang II treatment had no effect
on osteopontin mRNA or protein levels in these cells, despite the
previous finding of Mg Il-induced renal osteopontin levels in vivo
[91. In that study, infusion of Ang II to rats for two weeks elevated
blood pressure and induced severe tubular interstitial disease. The
failure of Ang II to induce osteopontin gene expression in
cultured renal epithelial cells suggests that the elevated levels
following Mg II infusion in vivo may have been due to an indirect
effect. One possibility is that Mg Il-induced renal damage might
increase either TGFJ3 or EGF, thereby leading to increased
osteopontin expression. However, we cannot rule out that the
NRK 52E cells used in these studies may lack or have few Ang Ii,
IGF, bFGF or PDGF receptors on the cell surface, or are
defective in specific cell signalling mechanisms. Consistent with
our results, EGF and TGFI3 receptors have been previously
identified in NRK 52E cells [23, 25, 26]. These possibilities are
currently being tested.
Acknowledgments
These studies were supported by NIH grant DK47659 and grant
EEC9529161 from the NSF. Dr. Giachelli is a Established Investigator of
the American Heart Association. We thank Alicia Momberg for her
technical support.
Reprint requests to Dr. Cecilia M. Giachelli, Ph.D., Pathology Department,
University of Washington, Vascular Biology, Box 357335, Seattle, Washington
98195, USA.
E-mail: ceci@)u. washington. edu
References
1. KuNclo GS, NEILSON EG, HAVERTY T: Mechanisms of tuhulointer-
stitial fibrosis. Kidney 1w' 39:550—556, 1991
2. DIAMOND JR, KEES FOLTS D, DING G, FRYE JE, RESTREPO NC:
Macrophages, monocyte chemoattractant peptide- 1, and TGF-beta 1
in experimental hydronephrosis. Am J Physiol 266:F926—F933, 1994
3. SCHREINER GF, HARRIS KPG, PURKERSON ML, KLAHR S: Immuno-
logical aspects of acute ureteral obstruction. Kidney mt 34:487—493,
1988
4. HARRIS KPG, SCHREINER GF, PURKERSON ML, KLAHR S: Effect of
leukocyte depletion on the post-obstructed rat kidney. Kidney mt
36:210-215, 1989
5. KLAHR 5: New insights into the consequences and mechanisms of
renal impairment in obstructive nephropathy. Am J Kidney Dis
18:689—699, 1991
6. BOHLE A, MACKENSEN-HAEN 5, VON GISE H: Significance of tubulo-
interstitial changes in the renal cortex for the excretory function and
concentration ability of the kidney: A morphometric contribution.
Am J Nephrol 7:421—433, 1987
7. STRIKER GE, SCHAINUCK LE, CUTLER RE, BENDITr EP: Structural-
functional correlations in renal disease. 1. The correlations. Hum
Pathol 1:615—630, 1987
8. GIACHELLI CM, SCHWARTZ SM, LIAW L: Molecular and cellular
biology of osteopontin: Potential role in cardiovascular disease. Trend
Cardiovasc Med 5:88—95, 1995
9. GIACHELLI CM, PICHLER R, LOMBARD! D, DENHARDT DT, ALPERS
CE, SCHWARTZ SM, JOHNSON Ri: Osteopontin expression in angio-
tensin TI-induced tubulointerstitial nephritis. Kidney mt 45:515—524,
1994
10. SFIIRAGA H, MIN W, VAN DUSEN WJ, CLAYMAN MD, MINER D,
TERRELL CH, SHERBOTIE JR, FOREMAN JW, PRZYSIECKI C, NEILSON
EG, HOYER JR: Inhibition of calcium oxalate crystal growth in vitro by
uropontin: Another member of the aspartic acid-rich protein super-
family. Proc Nat! Acad Sci USA 89:426—430, 1992
11. PICHLER R, GIACHELLI CM, LOMBARD! D, PIPPIN J, GORDON K,
ALPERS CE, SCHWARTZ SM, JOHNSON RJ: Tubulointerstitial disease in
glomerulonephritis: Potential role of osteopontin (uropontin). Am J
Pathol 144:915—926, 1994
12. PICHLER RHT, FRANCESCI-JINI N, YOUNG BA, HUGO C, ANDOH I,
BURDMANN E, SHANKLAND SJ, GIACHELI,I CM, ALPERS CE, BENNETr
WM, COUSER WG, JOHNSON RJ: Pathogenesis of cyclosporine ne-
phropathy: Roles of angiotensin II and osteopontin. JAm Soc Nephrol
6:1186—1196, 1995
13. EDDY AA, GIACHELLI CM: Renal expression of genes that promote
interstitial inflammation and fibrosis in rats with protein-overload
proteinuria. Kidney mt 47:1546—1557, 1995
14. DIAMOND JR, KEES-FOLTS D, RICARDO SD, PRUZNAK A, EUFEMIO M:
Early and persistent up-regulation of renal cortical osteopontin in
experimental hydronephrosis. Am I Pathol 146:1455—1466, 1995
15. SINGH RP, PATARCA R, SCHWARTZ J, SINGH P, CANTOR H: Definition
of a specific interaction between early T lymphocyte activation 1
(Eta-i) protein and murine macrophages in vitro and its effect upon
macrophages in vivo. J Exp Med 171:1931—1942, 1990
16. LOMBARDI DM, MOMBERG AA, JOHNSON R, PICHLER R, MURRY CE,
GIACHELLI CM: Neutralizing antibodies directed against osteopontin
inhibit f-met-leu-phe (FMLP)-induced macrophage infiltration in rat
skin. FASEB J 10:A1293, 1996
17. NASU K, IHIDA T, SETOGUCHI M, HIGUCHI Y, AKIZUKI 5, YAMAMOTO
5: Expression of wild-type and mutated rabbit osteopontin in Esche-
richia coli and their effects on adhesion and migration of P388D1 cells.
Biochem J 307:257—265, 1995
18. PADANILAM BJ, MARTIN DR, HAMMERMAN MR: Insulin-like growth
factor I-enhanced renal expression of osteopontin following acute
ischemic injury in rat. Endocrinol 137:2133—2140, 1996
19. MILLER SB, MARTIN DR, KISSANE J, HAMMERMAN MR: Insulin-like
growth factor I accelerates recovery from isehemic acute tubular
necrosis in the rat. Proc Nat! Acad Sci USA 89:11876—11880, 1992
20. LE QC, DAVIS CL, GIACHELLI CM, JOHNSON Ri, HUDKINS KL,
ALPERS CE: Osteopontin expression in renal transplant biopsies.
(abstract) Lab Invest 70:158A, 1994
21. HWANG 5, LOPEZ CA, HECK DE, GARDNER CR, LASKIN DL, LASKIN
JD, DENHARDT DT: Osteopontin inhibits induction of nitric oxide
synthase gene expression by inflammatory mediators in mouse kidney
epithelial cells. J Biol Chew 269:711—715, 1994
22. PICHLER R, GIACHELLI C, YOUNG B, ALF'ERS CE, COUSER WG,
JOHNSON RJ: The pathogenesis of tubulointerstitial disease associated
with glomerulonephritis: The glomerular cytokine theory. Miner Elec-
tra! Metab 21:317—327, 1995
23. DE LARCO JE, TODARO GJ: Epithelioid and fibroblastic rat kidney cell
clones: epidermal growth factor (EGF) receptors and the effect of
mouse sarcoma virus transformation. J Cell Physiol 94:335—342, 1978
24. SUZUKI E, HIRATA Y, HAYAKAWA H, OMATA M, KOJIMA M, KAN-
GAWA K, MINAMINO N, MAIsuo H: Evidence for C-type natriuretic
peptide production in the rat kidney. Biochem Biophys Res Common
192:532—538, 1993
25. WALKER C, EVERITI J, FREED JJ, KNUDSON AG, WHITELY LO:
Altered expression of transforming growth factor-alpha in hereditary
rat renal cell carcinoma. Cancer Res 5 1:2973—2978, 1991
Malyankar et al: Osteopontin regulation in kidney cells 1773
26. FRANCH HA, SHAY JW, ALPERN RJ, PREIsIG PA: Involvement of pRB
family in TGF beta-dependent epithelial cell hypertrophy. J Cell Biol
129:245—254, 1995
27. GIACHELLI CM, BAE N, L0MBARDI D, MAJESKY M, SCHWARTZ SM:
Molecular cloning and characterization of 2B7, a rat mRNA which
distinguishes smooth muscle cell phenotypes in vitro and is identical to
osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Rex
Commun 177:867—873, 1991
28. MURRY CE, GIACHELLI CM, SCHWARTZ SM, VRACK0 R: Macro-
phages express osteopontin during repair of myocardial necrosis. Am J
Pathol 145:1450—1462, 1994
29. GIACHELLI CM, BAE N, ALMEIDA M, DENHARDT DT, ALPERS CE,
SCHWARTZ SM: Osteopontin is elevated during neointima formation
in rat arteries and is a novel component of human atherosclerotic
plaques. J Clin Invest 92:1686—1696, 1993
30. LIAW L, ALMEIDA M, HART CE, SCHWARTZ SM, GIACHELLI CM:
Osteopontin promotes vascular cell adhesion and spreading and is
chemotactic for smooth muscle cells in vitro. Circ Res 74:214—224,
1994
31. GIACHELLI CM, MAJESKY MW, SCHWARTZ SM: Developmentally
regulated cytochrome P4501A1 expression in cultured rat vascular
smooth muscle cells. J Biol Chem 266:3981—3986, 1991
32. AUSUBEL FM, BRENT R, KINGSTON RE, MooRE DD, SEIDMAN JG,
SMITH JA, STRUHL K: Current Protocols in Molecular Biology. John
Wiley and Sons, Inc. 1994, pp 4.10.1—4.10.3
33. DEGEN JL, NEUBAUER MG, FRIEZNER SJ, SEYFRIEDCE, MORRIS DR:
Regulation of protein synthesis in mitogen-activated bovine lympho-
cytes. J Biol Chem 258:12153—12162, 1983
34. UMEKAWA T, YAMATE T, AMASAKI N, KOHRI K, KURITA T: Osteopon-
tin mRNA in the kidney on an experimental rat model of renal stone
formation without renal failure. Urol mt aSS:6—10, 1995
35. SHANKLAND SJ, PIPPIN J, PICHLER RH, GORDON KL, FRIEDMAN 5,
GOLD LI, JOHNSON RJ, COUSER WG: Differential expression of
transforming growth factor beta isoforms and receptors in experimen-
tal membranous nephropathy. Kidney Int 50:116—124, 1996
36. DING G, PESEK-DIAMOND I, DIAMOND JR: Cholesterol, macrophages,
and gene expression of TGF-B and fibronectin during nephrosis. Am J
Physiol 264:F577—584, 1993
37. COIMBRA T, WIGGINS R, NOH JW, MERRITF 5, PHAN SH: Transform-
ing growth factor beta production in anti-glomerular basement mem-
brane disease in the rabbit. Am J Pathol 138:223—243, 1991
38. YAMAMOTO T, NAKAMURA T, NOBLE NA, RUOSLAHTI E, BORDER
WA: Expression of transforming growth factor beta is elevated in
human and experimental diabetic nephropathy. Proc Natl Acad Sci
USA 90:1814—1818, 1993
39. SHANKLAND SJ, SCHOLEY JW: Expression of transforming growth
factor Bi during diabetic renal hypertrophy. Kidney lot 46:430—442,
1994
40. BORDER WA, OKUDA 5, LANGUINO LR, SPORN MB, RUOSLAHTI E:
Suppression of experimental glomerulonephritis by antiserum against
transforming growth factor Bi. Nature 346—374:1990
41. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI Y,
PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of transforming
growth factor beta protects against scarring in experimental kidney
disease. Nature 360:361—364, 1992
42. SIIARMA K, YULIN J, Guo J, ZIYADEH: Neutralization of TGF-B by
anti-TGF-13 antibody attenuates kidney hypertrophy and the en-
hanced extracellular matrix gene expression in streptozotocin-diahetic
mice. Diabetes 45:522—530, 1996
43. VERSTREPEN WA, NOUWEN EJ, ZHU MO, GIIIELLI M, DEBROE ME:
Time course of growth factor expression in mercuric chloride acute
renal failure. Nephrol Dial Transplant 10:1361—1371, 1995
44. TAIRA T, YOSHIMURA A, IIZUKA K, INUI K, OSHIDEN K, IWASAKI 5,
IDEURA T, KOSHIKAWA 5: Expression of epidermal growth factor and
its receptor in rabbits with isehaemic acute renal failure. Virchows
Arch 427:583—588, 1996
45. COWLEY BD, GUDAPATY 5: Temporal alterations in regional gene
expression after nephrotoxic renal injury.J Lab Clin Med 125:187—199,
1995
46. HUMES HD, CIISLINSKI DA, COIMBRA TM, MESSANA JM, GALVAO C:
Epidermal growth factor enhances renal tubule cell regeneration and
repair and accelerates the recovery of renal function in post-isehemic
acute renal failure. J Clin Invest 84:1757—1761, 1989
47. COIMBRA TM, CIESLINSKI DA, HOMES HD: Epidermal growth factor
accelerates renal repair in mercuric chloride nephrotoxicity. Am J
Physiol 259:F438—F443, 1990
48. KUBOTA T, ZHANG 0, WRANA JL, BER R, AUBIN JE, BUTLER WT,
SODEK J: Multiple forms of sppl (secreted phosphoprotein, osteopon-
tin) synthesized by normal and transformed rat bone cell populations:
Regulation by TGF. Biochem Biophys Rex Commun 162:1453—1459,
1989
49. RooN SB, WES0L0wSKI G, YooN K, RODAN GA: Opposing effects of
fibroblast growth factor and pertussis toxin on alkaline phosphatase,
osteopontin, osteocalcin, and type I collagen mRNA levels in ROS
17/2.8 cells. J Biol Chem 264:19934—19941, 1989
50. GREEN RS, LIEB ME, WEINTRAUB AS, GACHERU SN, ROSENFIELD
CL, SHAH 5, KAGAN HM, TAUBMAN MB: Identification of lysyl
oxidase and other platelet-derived growth factor-inducible genes in
vascular smooth muscle cells by differential screening. Lab Invest
73:476—482, 1995
51. NODA M, VOGEL RL, HASSON DM, RODAN GA: Leukemia Inhibitory
factor suppresses proliferation, alkaline phosphatase activity, and type
I collagen messenger RNA level and enhances osteopontin mRNA
level in murine osteoblast-like (MC3T3EI) cells. Endocrinol 127:185—
190, 1990
52. JIN CH, MIYAURA C, ISHIMI Y, HONG MH, SAT0 T, ABE E, SODA T:
Interleukin 1 regulated the expression of osteopontin mRNA by
osteoblasts. Mol Cell Endocrinol 74:221—228, 1990
53. NODA M, RODAN GA: Type beta transforming growth factor regulates
expression of genes encoding bone matrix proteins. Connective Tis Res
21:71—75, 1989
54. DusoIS CM, RUSCETrI RW, STANKOVA J, KELLER JR: Transforming
growth factor-beta regulates c-kit message stability and cell-surface
protein expression in hematopoietic progenitors. Blood 83:3138—3145,
1994
55. FINDER J, STARK WW, NAKAYAMA DK, GELLER D, WAS5ERLOOS K,
Purr BR, DAVIES P: TGF-beta regulates production of NO in pulmo-
nary artery smooth msucle cells by inhibiting expression of NOS. Am J
Physiol 268:862—867, 1995
